文献速递疼痛医学术前评估与围术期医学

鞘内药物输注实用指南:短期与长期管理及并发症

Practical guide to intrathecal drug delivery: short-term and long-term management and complications.
PubMed 文献 · Reg Anesth Pain Med · 2026-09-08

该实用指南综合现有证据、共识推荐和国际临床经验,针对可植入鞘内药物输注(IDD)系统的短期与长期管理提供结构化方法,涵盖患者选择、试验策略、装置选择、围术期管理、并发症监测及鞘内药物策略,强调功能改善与生活质量等结局,并区分癌症与非癌症人群的治疗目标差异。

要点

  • IDD可靶向脊髓给药,以低于全身治疗的剂量实现持久症状控制并减少全身用药负担。
  • 指南覆盖术前评估、试验策略、泵与导管选择、围术期管理及长期并发症监测。
  • 癌症与非癌症人群在治疗目标、时间窗和风险容忍度上存在差异,需纳入决策框架。

核心结论

  • IDD是难治性癌性与非癌性疼痛的成熟疗法,但临床应用不足且集中于高流量中心。
  • 本指南整合证据与经验,为IDD全生命周期提供结构化、实用的管理框架。

研究设计与样本

  • 实用指南类文献,综合当前证据、共识推荐与集体国际临床经验。

主要发现

  • IDD以低于全身治疗的剂量实现靶向脊髓给药,可提供持久症状控制并减少全身用药负担与治疗限制性不良反应。
  • 指南涵盖术前评估与风险缓解、试验策略及其局限、泵与导管选择、围术期管理、植入后早期排障、长期维护及装置相关并发症监测。
  • 鞘内药物策略包括阿片类、局麻药、齐考诺肽、可乐定和巴氯芬,需关注适应证特异性给药、滴定与安全性。
  • 临床结局应超越疼痛强度,纳入功能改善、生活质量及全身用药减少作为有临床意义的终点。

关键数值与推荐

  • IDD适用于癌症与非癌症人群的难治性疼痛。
  • 癌症特异性考量包括预后、与肿瘤治疗的协调、脊柱解剖变化及压缩的治疗时间窗。

临床怎么用

  • 对难治性疼痛患者应评估IDD适应证,并依据指南进行术前评估、试验及装置规划。
  • 围术期及长期随访中需系统监测装置相关、生物性及操作性并发症。
  • 癌症患者需结合预后与肿瘤治疗协调制定IDD策略,非癌症患者需考虑长期管理目标。

局限性

  • 原文提及IDD证据有限。
  • 原文提及患者选择、试验及长期管理存在持续不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intrathecal drug delivery (IDD) is an established therapy for patients with refractory pain across cancer and non-cancer populations. By enabling targeted spinal drug delivery, IDD can provide durable symptom control at substantially lower doses than systemic therapy, often reducing systemic medication burden and treatment-limiting adverse effects. Despite decades of clinical experience and supportive evidence, IDD remains underutilized and largely concentrated in high-volume centers, reflecting persistent uncertainty related to patient selection, trialing, device planning, long-term management, limited evidence, and complication mitigation.This practical guide synthesizes current evidence, consensus recommendations, and collective international clinical experience to provide a structured approach to short-term and long-term management of implantable IDD systems. Shared principles applicable across indications are emphasized, while cancer-specific considerations are addressed separately, including prognosis, coordination with oncologic therapies, evolving spinal anatomy, and compressed treatment horizons. Key topics include preimplant evaluation and risk mitigation, trialing strategies and their limitations, pump and catheter selection, perioperative management, early post-implant troubleshooting, long-term maintenance, and surveillance for device-related, biological, and operational complications. Intrathecal pharmacologic strategies for pain are examined, including opioids, local anesthetics, ziconotide, clonidine, and baclofen, with attention to indication-specific dosing, titration, and safety considerations.Clinical outcomes are framed beyond pain intensity alone, emphasizing functional improvement, quality of life, and reduction in systemic medication use as clinically meaningful endpoints. Differences in therapeutic goals, time horizons, and risk tolerance between cancer and non-cancer populations are integrated into a practical decision framework aligned with real-world pain practice. International and regional practice variations are also discussed to contextualize differences in drug availability, compounding practices, and reimbursement. By consolidating pragmatic guidance across the full lifecycle of intrathecal therapy, this guide aims to support consistent, safe, and effective use of IDD for complex pain management in contemporary practice.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Sivanesan E, Bienfait F, Chen Y, et al. Practical guide to intrathecal drug delivery: short-term and long-term management and complications. Reg Anesth Pain Med. 2026. PMID: 42710948. doi:10.1136/rapm-2025-107404

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。